Elbasvir/grazoprevir
| Combination of | |
|---|---|
| Elbasvir | NS5A inhibitor |
| Grazoprevir | NS3/4A protease inhibitor |
| Clinical data | |
| Trade names | Zepatier |
| AHFS/Drugs.com | zepatier |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| KEGG | |
Elbasvir/grazoprevir, sold under the brand name Zepatier, is a fixed-dose combination for the treatment of hepatitis C, containing elbasvir (an inhibitor of hepatitis C virus's NS5A protein) and grazoprevir (an NS3/4A inhibitor). It is used to treat chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in both treatment-naïve and treatment-experienced patients.[3]
Both elbasvir and grazoprevir were developed by Merck & Co. The US Food and Drug Administration (FDA) approved the drug in January 2016.[5]
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
- ^ a b "Zepatier- elbasvir and grazoprevir tablet, film coated". DailyMed. 25 May 2022. Retrieved 20 May 2023.
- ^ "Zepatier EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 8 July 2022. Retrieved 8 July 2022.
- ^ "FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4". U.S. Food and Drug Administration (FDA) (Press release). 28 January 2016. Archived from the original on 23 April 2019. Retrieved 31 January 2016.